BB BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.45 CHF | -0.25% |
|
-2.29% | -5.38% |
| 04-26 | Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps | MT |
| 04-25 | BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 190M 208M 16.64B | Sales 2025 * | 101M 110M 8.82B | Capitalization | 2.22B 2.43B 194B |
|---|---|---|---|---|---|
| Net income 2024 * | 152M 166M 13.31B | Net income 2025 * | 72M 78.72M 6.31B | EV / Sales 2024 * | 13.2 x |
| Net Debt 2024 * | 291M 318M 25.49B | Net Debt 2025 * | 324M 355M 28.42B | EV / Sales 2025 * | 25.3 x |
| P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
13.6
x | Employees | 10 |
| Yield 2024 * |
5.81% | Yield 2025 * |
5.93% | Free-Float | 97.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.25% | ||
| 1 week | -2.29% | ||
| Current month | -11.20% | ||
| 1 month | -10.80% | ||
| 3 months | -8.28% | ||
| 6 months | +11.89% | ||
| Current year | -5.38% |
1 week
40.20
41.60
1 month
40.2045.90
Current year
40.2049.80
1 year
35.3549.80
3 years
35.3592.40
5 years
35.3593.45
10 years
28.3093.45
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 31/12/03 |
| - | - | ||
| - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 31/12/03 |
| Director/Board Member | 63 | 31/12/19 | |
| Chairman | 63 | 20/03/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 40.45 | -0.25% | 51,176 |
| 25/04/24 | 40.55 | -2.17% | 59,657 |
| 24/04/24 | 41.45 | -0.36% | 57,148 |
| 23/04/24 | 41.6 | +0.97% | 113,601 |
| 22/04/24 | 41.2 | -0.48% | 63,519 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotes
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Calendar
26/07/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.45
CHF
Average target price
47.7
CHF
Spread / Average Target
+17.92%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.38% | 2.43B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BION Stock
